Among the breast cancer subtypes, hormone receptor-positive tumors respond to endocrine therapy, while endocrine therapy is not beneficial for triple negative tumors, as they do not express hormone receptors, making it difficult to treat with currently available breast cancer treatments [2]. Here, NR4A1 is linked to breast carcinoma.